We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN (COCY)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2011 by The University of Hong Kong.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01058460
First Posted: January 28, 2010
Last Update Posted: June 1, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
The Family Planning Association of Hong Kong
Information provided by:
The University of Hong Kong
  Purpose

To compare the effects of conventional cytology testing with concommitant HPV-cytology testing for the detection of high grade cervical lesions in primary cervical cancer screening in Hong Kong

Hypotheses:

  1. There is a significant difference in the number of CIN2+ cases detected between the cytology testing group and the cytology-HPV co-testing group at baseline.
  2. Significantly more CIN2+ cases will be detected at the second round of screening among participants with normal cytology result in the control arm than those with normal cytology and negative HPV results in the intervention arm.

Condition Intervention
Cervical Cancer Cervical Intraepithelial Neoplasia Procedure: HPV-cytology co-testing

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized Controlled Trial Comparing Concomitant HPV-cytology Testing With Conventional Cytology Testing for the Detection of High Grade Cervical Intraepithelial Neoplasia in Primary Cervical Cancer Screening in Hong Kong

Resource links provided by NLM:


Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • Histological CIN2, CIN3 and cervical carcinoma [ Time Frame: At baseline and each subsequent follow-up ]

Secondary Outcome Measures:
  • Clearance of mild cervical abnormalities among HPV negative subjects [ Time Frame: At baseline and 1-year after ]

Estimated Enrollment: 12000
Study Start Date: June 2010
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: cytology
Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
Experimental: HPV-cytology
Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
Procedure: HPV-cytology co-testing
Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ethnic Chinese women aged 30 to 60 years who have completed a written consent
  • Women who have not attended screening for the past 3 years or more will be given priority

Exclusion Criteria:

  • Currently pregnant
  • Without a cervix
  • Congenital abnormalities of the lower genital tract
  • Previous history of invasive cervical cancer
  • Who has been followed-up or treated for an abnormal cytology result in the past 12 months
  • Who are unable to provide consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01058460


Contacts
Contact: Hextan YS Ngan, MD, MBBS 852-2255-4684 hysngan@hkusua.hku.hk

Locations
China
Department of Obstetrics & Gynaecology, The University of Hong Kong Recruiting
Hong Kong SAR, China
Principal Investigator: Hextan YS Ngan, MD, MBBS         
Sponsors and Collaborators
The University of Hong Kong
The Family Planning Association of Hong Kong
Investigators
Principal Investigator: Hextan YS Ngan, MD, MBBS Department of Obstetrics & Gynaecology, The University of Hong Kong
  More Information

Responsible Party: Professor Hextan Y.S. Ngan, Department of Obstetrics & Gynaecology, The University of Hong Kong
ClinicalTrials.gov Identifier: NCT01058460     History of Changes
Other Study ID Numbers: UW09-377
First Submitted: January 27, 2010
First Posted: January 28, 2010
Last Update Posted: June 1, 2011
Last Verified: May 2011

Keywords provided by The University of Hong Kong:
Cervical Intraepithelial Neoplasia, Grade III
Cervical Intraepithelial Neoplasia, Grade II

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Neoplasms
Carcinoma in Situ
Cervical Intraepithelial Neoplasia
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type